Skip to content

Lung Cancer Diagnosis by Detecting Epigenetic Imprinting Alterations in Bronchoalveolar Lavage

A Multicenter Study for Evaluating the Benign and Malignant Pulmonary Noldules by Detecting the Epigenetic Imprinting Alterations in Bronchoalveolar Lavage

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05707585
Enrollment
2064
Registered
2023-02-01
Start date
2023-01-29
Completion date
2024-07-15
Last updated
2023-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Genomic Imprinting, Epigenetics, Diagnostic Study, Bronchoalveolar Lavage

Brief summary

The goal of this multicenter observational study is to evaluate the lung cancer diagnostic value of epigenetic imprinting detection in bronchoalveolar lavage. This study will mainly focus on varifing the previously identified epigenetic imprinting biomarkers for lung cancer and upgrading and validating a lung cancer imprinting diagnostic model specifically for bronchoalveolar lavage. The lavage sample will be collected from each eligible paticipants under bronchialscopy and undergo QCIGISH detection to analyze the allelic expression status of imprinted genes. The QCIGISH detection results will be compared with the final surgical histopathology. No interventions will be taken according to the QCIGISH detection results.

Detailed description

Bronchial biopsy and bursh are widely used in lung cancer diagnosis but not bronchoalveolar lavage because of its low sensitivity. As the molecular alterations usually occur before the morphological changes, genetic and epigenetic biomarkers will be helpful for early diagnosis of cancers. As an important epigenetic regulation in mammalian embryo development, genomic imprinting plays important roles in cancers. In normal post-natal somatic cells, imprinted genes are silenced, that is mono-allelically expressed either from the maternal or paternal allele, while in cancers, some silenced imprinting genes' copies could be reactivated, leading to expressions from both alleles. The loss of monoallelic gene regulation is named loss of imprinting (LOI), and has been previously found in various human cancers. Our previous studies has identified several imprinted genes with elevated aberrant allelic expressions in lung cancer. A diagnostic model based on the epigenetic imprinting biomarkers achieved 99.1% sensitivity and 92.1% specificity. In this study, we will first verify the epigenetic imprinting biomarkers in bronchoalveolar lavage, and refine the previously developed diagnostic model specifically for lavage samples. The diagnostic model will be independently validated in a group of prospectively enrolled cases. This study will help to distinguish benign and malignant pulmonary nodules presurgically, and improve the early diagnosis of lung cancer.

Interventions

DIAGNOSTIC_TESTQuantitative Chromogenic Imprinted Gene in situ Hybridization (QCIGISH)

Visualize and quantify the allelic expression status of imprinted genes by in situ hybridization using probes targeting the nascent RNAs

Sponsors

Fudan University
CollaboratorOTHER
Zongda Hospital affiliated to Southeast University
CollaboratorNETWORK
West China Hospital
CollaboratorOTHER
Henan Provincial People's Hospital
CollaboratorOTHER
First Hospital of China Medical University
CollaboratorOTHER
Shengjing Hospital
CollaboratorOTHER
The First Affiliated Hospital of Guangzhou Medical University
CollaboratorOTHER
Lisen Imprinting Diagnostics, Inc.
CollaboratorUNKNOWN
The Second Affiliated Hospital of Dalian Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years old, and ≤ 75 years old; * Chest CT showed pulmonary nodule with diameter\<3cm; * Subjects voluntarily participated and signed the informed consent form.

Exclusion criteria

* Active massive hemoptysis; * Severe heart and lung dysfunction; * Severe arrhythmia; * Extreme exhaustion of general condition; * Coagulation dysfunction; * Acute attack of asthma; * Aortic aneurysm.

Design outcomes

Primary

MeasureTime frameDescription
Epigenetic Imprinting Diagnostic ScoreWithin 10 days after each sample collectedCancer risk scores calculated by combining the biallelic expressions, multiallelic expressions and total expressions of several imprinted genes

Countries

China

Contacts

Primary ContactEncheng Li, MD
doctorliencheng@163.com+86-411-84671291

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026